Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP

PHASE3

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped AnaptysBio has concluded the GEMINI-2 trial, with all trial participants having been treated with imsidolimab for approximately six months and the furthest subject having been treated through 104 weeks.

Conditions

Generalized Pustular Psoriasis

Interventions

DRUG: Double-blind 200 mg imsidolimab
OTHER: Placebo
DRUG: Open-label 200 mg imsidolimab
OTHER: Standard of Care (SOC)
DRUG: Imsidolimab 750 mg IV/200 mg SC

Sponsor

Vanda Pharmaceuticals